BioPharma Credit Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Net Income	123.12	122.18	108.45	182.31	84.96	89.14	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	-	-	-9.46	Upgrade
Loss (Gain) From Sale of Investments	-11.37	0.09	23.95	-5.95	23.75	-	Upgrade
Other Operating Activities	-0.02	0	0.01	0.03	0.02	-21.76	Upgrade
Change in Accounts Receivable	-17.67	-11.48	-0.48	-9.83	-9.8	16	Upgrade
Change in Accounts Payable	3.96	1.12	-8.74	17.71	-2.49	-15.84	Upgrade
Operating Cash Flow	98.03	111.91	123.18	184.28	96.44	58.07	Upgrade
Operating Cash Flow Growth	-30.19%	-9.15%	-33.15%	91.09%	66.06%	-55.84%	Upgrade
Investment in Securities	70	39.07	-1.66	48.19	-94.82	-47.47	Upgrade
Investing Cash Flow	70	39.07	-1.66	48.19	-94.82	-47.47	Upgrade
Repurchase of Common Stock	-80.31	-105.75	-17.22	-50.09	-	-0.06	Upgrade
Common Dividends Paid	-56.65	-109.02	-68.95	-95.74	-96.17	-96.17	Upgrade
Financing Cash Flow	-200.89	-280.42	-106.99	-206.62	-100.16	-113.96	Upgrade
Foreign Exchange Rate Adjustments	0.02	-0	-0.01	-0.03	-0.02	-0.01	Upgrade
Net Cash Flow	-32.84	-129.43	14.53	25.82	-98.56	-103.37	Upgrade
Levered Free Cash Flow	63.32	66.9	56.88	124.09	40.26	56.6	Upgrade
Unlevered Free Cash Flow	63.32	66.9	56.88	124.09	40.26	56.6	Upgrade
Change in Working Capital	-13.71	-10.36	-9.22	7.88	-12.29	0.16	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.